UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, DCD.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~September~~February 2210, ~~2014~~2015

PAR PHARMACEUTICAL COMPANIES, INC.

(Exact name of registrant as specified in its charter)

Delaware	~~File Number~~ 1-10827	22-~~3122182~~312218
(State or other jurisdiction of	(Commission	(I.R.S. Employer
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. EmployerIdentification No.)
incorporation or organization)	File Number)	Identification No.)
300 Tice Boulevard, Woodcliff Lake, NJ		07677
(Address of principal executive offices)		(Zip Code)


300 Tice Boulevard, Woodcliff Lake, NJ				07677
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (201) 802-4000

Former name or former address, if changed since last report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 82.0102. ~~Other~~Results ~~Events~~of Operations and Financial Condition.

OnThis ~~September 22,~~Current ~~2014~~Report ~~(the~~on ~~“Effective~~Form ~~Date”),~~8-K ~~the Company entered into a settlement agreement with Salix Pharmaceuticals, Inc.~~ (this “~~Salix”),~~Form ~~Santarus, Inc. (“Santarus~~8-K”) ~~and~~is ~~The~~being ~~Curators~~furnished ofto ~~the~~disclose ~~University~~certain ofinformation ~~Missouri~~ (~~“Missouri”~~the ~~and, collectively with Salix and Santarus,~~ “~~Plaintiff Releasors~~Selected Information”) ~~to resolve all claims relating to the Company’s sales~~, ~~commencing~~including incertain ~~July~~estimated ~~2010,~~results of ~~its 20 mg and 40 mg generic Zegerid® (omeprazole/sodium bicarbonate) capsules. As part of the settlement~~operations, ~~which~~that ~~provides~~Par ~~for~~Pharmaceutical ~~the release of all claims against the Company and its affiliates~~Companies, ~~the Company agreed to pay $100 million to Plaintiff Releasors within five business days after the Effective Date~~Inc. ~~The~~(the “Company”), will ~~pay~~furnish ~~such~~to ~~amount~~prospective ~~from~~debt ~~currently~~financing ~~available~~sources ~~cash~~in ~~and~~connection ~~will~~with ~~record~~ a ~~charge~~potential ~~of approximately~~ $~~91 million~~425 ~~in the third quarter of 2014 in addition to the $9~~ million ~~previously~~incremental ~~accrued.~~term ~~The~~loan ~~Company currently anticipates that this settlement will be fully deductible for U~~financing.S. ~~income tax purposes.~~

AsItem previously reported, on September 13, 2007, Santarus and Missouri filed a lawsuit against the Company in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 6,699,885; 6,489,346; and 6,645,988 because the Company submitted an ANDA with a Paragraph IV certification seeking FDA approval of 20 mg and 40 mg omeprazole/sodium bicarbonate capsules. On December 20, 2007, Santarus and Missouri filed a second lawsuit alleging infringement of the patents because the Company submitted an ANDA with a Paragraph IV certification seeking FDA approval of 20 mg and 40 mg omeprazole/sodium bicarbonate powders for oral suspension. On October 20, 2008, plaintiffs amended their complaint to add U.S. Patent Nos. 6,780,882 and 7~~,399,722~~. ~~On April 14, 2010, the District Court ruled in the Company’s favor, finding that the plaintiffs’ patents were invalid as being obvious and without adequate written description~~01. OnRegulation ~~July 1,~~FD ~~2010, the Company launched its 20 mg and 40 mg generic omeprazole/sodium bicarbonate capsules product~~Disclosure. Santarus and Missouri appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit, and the Company cross-appealed the District Court’s decision of enforceability of plaintiffs’ patents. On September 4, 2012, the Court of Appeals reversed the District Court’s finding of invalidity and remanded to the District Court for further proceedings, and the Company ceased further distribution of its 20 mg and 40 mg generic omeprazole/sodium bicarbonate capsules product. Santarus was acquired by Salix on January 2, 2014.

~~Pursuant~~The todisclosure ~~the~~in ~~settlement agreement, the parties will enter into a stipulation, dismissing the case with prejudice~~Item 2.02 ~~The~~above ~~Company~~is ~~has~~hereby ~~agreed to refrain from~~incorporated ~~the~~by ~~reintroduction~~reference ofinto ~~its~~this ~~generic Zegerid® products until the expiration of plaintiffs’ patents, the unextended terms of which end July~~Item ~~16, 2016~~7.01.

~~Certain~~The ~~statements~~information contained in ~~this~~Item 2.02 ~~Current~~and ~~Report~~Item 7.01 onof this Form 8-K, ~~constitute~~including ~~“forward-looking statements” within~~ the exhibit ~~meaning~~hereto, ofis ~~the~~furnished ~~Private~~pursuant ~~Securities Litigation~~to ~~Reform~~Item 2.02 ~~Act~~and ~~of 1995~~Item 7.01 Toof ~~the extent that any statements made in this Current Report on~~ Form 8-K ~~contain~~and ~~information~~shall ~~that is~~ not ~~historical,~~in ~~such~~either ~~statements~~case ~~are~~be ~~essentially~~deemed ~~forward-looking~~“filed” ~~and~~for ~~are~~purposes ~~subject~~of toSection 18 ~~certain~~of ~~risks and uncertainties, including~~ the ~~risks~~Securities ~~and~~Exchange ~~uncertainties~~Act ~~discussed~~of ~~from~~1934, ~~time~~as toamended ~~time in~~ (the ~~Company’s filings with the SEC~~“Exchange Act”), ~~including~~or ~~its~~otherwise ~~Annual~~subject ~~Reports~~to onliability ~~Form~~under ~~10-K,~~that ~~Quarterly~~Section ~~Reports on Form 10-Q~~ and ~~Current~~shall ~~Reports~~not onbe ~~Form~~deemed ~~8-K.~~incorporated ~~Any~~by ~~forward-looking statements~~reference ~~included~~into inany ~~this~~filing ~~Current~~by ~~Report~~the onCompany ~~Form~~under ~~8-K~~the ~~are~~Securities ~~made~~Act as of ~~the~~1933, ~~date~~as ~~hereof only~~amended, ~~based~~or ~~on information available to~~ the ~~Company~~Exchange ~~as of the date hereof~~Act, ~~and,~~regardless ~~subject~~of to any ~~applicable law to the contrary, the Company assumes no obligation to~~general ~~update~~incorporation ~~any~~language ~~forward-looking~~in ~~statements~~such filing.

The Selected Information, contained in Exhibit 99.1 to this Form 8-K, is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in Exhibit 99.1, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. By furnishing the information in Item 7.01, Item 2.02 and in Exhibit 99.1, the Company makes no admission as to the materiality of any information contained herein or therein.

The Selected Information includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters including our estimate of financial results for the fiscal year ended December 31, 2014, including select pro forma financial results based on our estimate of financial results for the fiscal year ended December 31, 2014. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, finalizing the financial statements and completing the audits of the Company for the fiscal year ended December 31, 2014, and the risks identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013, and filed with the SEC, as well as the other information we file with the SEC. We caution investors, potential investors, and others not to place considerable reliance on the forward-looking statements contained in the Selected Information. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

99.1	Selected Information of Par Pharmaceutical Companies, Inc. provided to Prospective Debt Financing Sources, dated February 10, 2015.

~~SIGNATURES~~SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned ~~thereunto~~hereunto duly authorized.

Dated as of: September 22, 2014


		PAR PHARMACEUTICAL COMPANIES, INC.

By:		/s/ Paul V. Campanelli
Name:		Paul V. Campanelli
Title:		Chief Executive Officer

Date:		February 10, 2015

~~PAR~~3 ~~PHARMACEUTICAL COMPANIES, INC. (Registrant) /s/ Paul V. Campanelli Paul V. Campanelli, Chief Executive Officer~~

EXHIBIT INDEX


Exhibit No.		Description

99.1		Selected Information of Par Pharmaceutical Companies, Inc. provided to Prospective Debt Financing Sources, dated February 10, 2015.

Filing Compare · PAR PHARMACEUTICAL COMPANIES, INC.